Novo Nordisk A/s

Lars J Knutsen

Jesper F Lau

Knud Erik Andersen

Anker S Jorgensen

Ursula Sonnewald

Anker Jon Hansen

Malcolm Sheardown

Hans Petersen

Behrend Friedrich Lundt

Per O Sorensen

The present invention relates to compounds of formula I ##STR1## wherein X is amino, C.sub.1-6 -alkylamino, di-C.sub.1-6 -alkylamino;

Treatment of ischemias by administration of 2,N.sup.6 -substituted

A compound of formula (I), or a pharmaceutically acceptable salt thereof: ##STR1## wherein X is hydrogen, amino, halogen, hydroxy, lower alkoxy or lower alkyl and

Purine derivatives

A compound of formula (I), or a pharmaceutically acceptable salt thereof: ##STR1## wherein X is halogen, amino, perhalomethyl, cyano, C.sub.1-6 -alkoxy, C.sub.1-6 -alkylthio or C.sub.1-6 -alkylamino;

2,5',N6-trisubstituted adenosine derivatives

This application relates to methods of treating myocardial or cerebral ischemia, comprising administering a compound of formula I: ##STR1## wherein X is halogen, perhalomethyl, cyano, C.sub.1-6 -alkoxy, C.sub.1-6 -alkylthio or C.sub.1-6 -alkylamino; and

Methods of treating ischemia with C2, N.sup.6 -disubstituted adenosine

A compound of formula (I), or a pharmaceutically acceptable salt thereof: ##STR1## wherein X is halogen, trifluoromethyl, cyano, C.sub.1-6 -alkoxy, C.sub.1-6 -alkylthio, C.sub.1-6 -alkylamino or C.sub.1-6 -dialkylamino;

2, N.sup.6 -disubstituted adenosines, tri-O-ester derivatives and their

A compound of formula (I), or a pharmaceutically acceptable salt thereof: ##STR1## wherein X is halogen, perhalomethyl, cyano, C.sub.1-6 -alkoxy, C.sub.1-6 -alkylthio, or C.sub.1-6 -alkylamino; and

C2,N.sup.6 -disubstituted adenosine derivatives

Adenosine compounds having the following structure ##STR1## wherein X is halogen, perhalomethyl, acetamido, cyano, C.sub.1-6 -alkoxy, C.sub.1-6 -alkylthio or C.sub.1-6 -alkylamino; and R.sup.1 is --NR.sup.2 R.sup.3 or YR.sup.4, wherein Y is oxygen or sulfur; R.sup.2 is phenyl, C.sub.1-6 -alkyl or substituted C.sub.1-6 -alkyl; and R.sup.4 is naphthyl, partly saturated naphthyl; optionally phenyl or phenoxy substituted C.sub.1-6 -alkyl wherein the phenyl and phenoxy substituents are also optionally substituted, or optionally phenyl or phenoxy substituted C.sub.3-8 -cycloalkyl and their pharmaceutically acceptable salts are useful in the treatment of myocardial and cerebral ischemias.

2-chloro-N.sup.6 -substituted adenosines, their pharmaceutical

The invention relates to therapeutically active azaheterocyclic compounds and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating a central nervous system ailment related to the GABA uptake.

N-substituted azaheterocyclic carboxylic acids

Novel O-alkylated oximes of the general formula I ##STR1## or ##STR2## wherein R.sup.1 and R.sup.2 are optionally substituted aromatic or heteroaromatic rings, R.sup.3 is hydrogen or lower alkyl, R.sup.4 is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.

Azacyclic carboxylic acid derivatives and their preparation and use

Novel O-alkylated oximes of the general formula I ##STR1## wherein R.sup.1 and R.sup.2 are optionally substituted aromatic or heteroaromatic rings, R.sup.3 is hydrogen or lower alkyl, R.sup.4 is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA re-uptake from the synaptic cleft.

Novel O-alkylated oximes of the general formula I ##STR1## wherein R.sup.1 and R.sup.2 are optionally substituted aromatic or heteroaromatic rings, R.sup.3 is hydrogen or lower alkyl, R.sup.4 is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.

Growing community of inventors

Vedb k, Denmark

Lars J Knutsen